Sangamo Can Take Lead In Fabry Gene Therapy

Gearing Up For Phase III

 
• By Andrew McConaghie
  
Sangamo
The Fabry disease gene therapy is one of three candidates Sangamo has in its wholly-owned pipeline • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Rare Diseases

More from Scrip